The biological effects of five feline IFN-α subtypes

Veterinary Immunology and Immunopathology

Volumn 99, Issue 3-4, 2004, Pages 153-167

  Baldwin, Susan L ^a,b   Powell, Tim D ^a   Sellins, Karen S ^a,c   Radecki, Steven V ^a   Cohen, J John ^a,b   Milhausen, Michael J ^a  

^a HESKA CORPORATION   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Antiproliferation; Apoptosis; Feline calicivirus; Feline IFN ; Mx; Necrosis; Vesicular stomatitis virus

Indexed keywords

ALPHA INTERFERON; ALPHA1 INTERFERON; ALPHA2 INTERFERON; ALPHA3 INTERFERON; ALPHA5 INTERFERON; ALPHA6 INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CALICIVIRUS; CAT; CELL PROLIFERATION; CHO CELL; EMBRYO; FIBROBLAST; GENE; GENE CONTROL; KIDNEY CELL; MX GENE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PURIFICATION; T LYMPHOCYTE; UPREGULATION; VESICULAR STOMATITIS VIRUS; VIRUS INFECTION;

ANIMALS; BASE SEQUENCE; CALICIVIRIDAE INFECTIONS; CALICIVIRUS, FELINE; CAT DISEASES; CATS; CHO CELLS; CRICETINAE; CYTOPATHOGENIC EFFECT, VIRAL; FEMALE; FIBROBLASTS; GTP-BINDING PROTEINS; INHIBITORY CONCENTRATION 50; INTERFERON-ALPHA; MALE; MOLECULAR SEQUENCE DATA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOVIRIDAE INFECTIONS; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VESICULAR STOMATITIS-INDIANA VIRUS;

ANIMALIA; CALICIVIRIDAE; CRICETINAE; CRICETULUS GRISEUS; FELIDAE; FELINE CALICIVIRUS; PICHIA; PICHIA PASTORIS; VESICULAR STOMATITIS VIRUS;

EID: 2342650045     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2004.01.012     Document Type: Article

References (57)

1. Accola M.A., Huang B., Masri A.A., McNiven M.A. The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum. J. Biol. Chem. 277(24):2002;21829-21835
2. Baker P.K., Pettitt A.R., Slupsky J.R., Chen H.J., Glenn M.A., Zuzel M., Cawley J.C. Response of hairy cells to IFN-α involves induction of apoptosis through autocrine TNF-α and protection by adhesion. Blood. 100(2):2002;647-653
3. Binns S.H., Dawson S., Speakman A.J., Cuevas L.E., Hart C.A., Gaskell C.J., Morgan K.L., Gaskell R.M. A study of feline upper respiratory tract disease with reference to prevalence and risk factors for infection with feline calicivirus and feline herpesvirus. J. Feline Med. Surg. 2:2000;123-133
4. Brassard D.L., Grace M.J., Bordens R.W. Interferon-α as an immunotherapeutic protein. J. Leukoc. Biol. 71:2002;565-581
5. Caraglia M., Marra M., Giuberti G., D'Alessandro A.M., Baldi A., Tassone P., Venuta S., Tagliaferri P., Abbruzzese A. The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J. Biochem. (Tokyo). 133(6):2003;757-765
6. Couto, C.-G., 1992a. Lymphoma in the cat and dog. In: Nelson, R.W., Guillermo Couto, C. (Eds.), Essentials of Small Animal Internal Medicine. Mosby-Year Book Inc., St. Louis, MO, pp. 861-870.
7. Couto, C.-G., 1992b. Leukemias. In: Nelson, R.W., Guillermo Couto, C. (Eds.), Essentials of Small Animal Internal Medicine. Mosby-Year Book Inc., St. Louis, MO, pp. 871-878.
8. Cummins J.M., Tompkins M.B., Olsen R.G., Tompkins W.A., Lewis M.G. Oral use of human alpha interferon in cats. J. Biol. Response Mod. 7(5):1988;513-523
9. Dick C.P., Johnson R.P., Yamashiro S. Sites of persistence of feline calicivirus. Res. Vet. Sci. 47(3):1989;367-373
10. Duke, R.C., Cohen, J.J., 1992. Morphological and biochemical assays of apoptosis. In: Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Current Protocols in Immunology. Greene Publishing/Wiley/ Interscience, New York, pp. 3.17.1-3.17.16.
11. Foster G.R., Rodrigues O., Ghouze F., Schulte-Frohlinde E., Testa D., Liao M.J., Stark G.R., Leadbeater L., Thomas H.C. Different relative activities of human cell-derived interferon-α subtypes: IFN-α8 has very high antiviral potency. J. Interferon Cytokine Res. 16:1996;1027-1033
12. Fulton R.W., Burge L.J. Susceptibility of feline herpesvirus 1 and a feline calicivirus to feline interferon and recombinant human leukocyte interferons. Antimicrob. Agents Chemother. 28(5):1985;698-699
13. Gao X., Dinkova-Kostova A.T., Talalay P. Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: the indirect antioxidant effects of sulforaphane. PNAS. 98(26):2001;15221-15226
14. Gaskell C.J., Gaskell R.M., Dennis P.E., Wooldridge M.J. Efficacy of an inactivated feline calicivirus (FCV) vaccine against challenge with United Kingdom field strains and its interaction with the FCV carrier state. Res. Vet. Sci. 32(1):1982;23-26
15. Gaskell, R.M., Dawson, S., 1998. Feline respiratory disease. In: Greene, C.E. (Ed.), Infectious Diseases of the Dog and Cat, 2nd ed. WB Saunders, Philadelphia, pp. 97-106.
16. Goodbourn S., Didcock L., Randall R.E. Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81:2000;2341-2364
17. Gordien E., Rosmorduc O., Peltekian C., Garreau F., Brechot C., Kremsdorf D. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J. Virol. 75(6):2001;2684-2691
18. Haller O., Frese M., Rost D., Nuttall P.A., Kochs G. Tick-borne Thogoto virus infection in mice is inhibited by the orthomyxovirus resistance gene product Mx1. J. Virol. 69(4):1995;2596-2601
19. Hefti H.P., Frese M., Landis H., DiPaolo C., Aguzzi A., Haller O., Pavlovic J. Human MxA protein protects mice lacking a functional alpha/beta interferon system against La Crosse virus and other lethal viral infections. J. Virol. 73(8):1999;6984-6991
20. Hoover E.A., Kahn D.E. Experimentally induced feline calicivirus infection: clinical signs and lesions. J. Am. Vet. Med. Assoc. 166(5):1975;463-468
21. Hoover E.A., Zeidner N.S., Mullins J.I. Therapy of presymptomatic FeLV-induced immunodeficiency syndrome with AZT in combination with alpha interferon. Ann. NY Acad. Sci. 616:1990;258-269
22. Horisberger M.A., Schrenk R., Staiger S., Leyvraz A.R., Martinod S. Induction of Mx-related protein in cat peripheral blood mononuclear cells after administration of recombinant human interferon hybrid. Antiviral Res. 13(2):1990;53-59
23. Kitamura T., Tange T., Terasawa T., Chiba S., Kuwaki T., Miyagawa K., Piao Y.F., Miyazono K., Urabe A., Takaku F. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J. Cell Physiol. 140(2):1989;323-334
24. Kochs G., Janzen C., Hohenberg H., Haller O. Antivirally active MxA protein sequesters La Crosse virus nucleocapsid protein into perinuclear complexes. PNAS. 99(5):2002;3153-3158
25. Martin V., Najbar W., Gueguen S., Grousson D., Eun H.M., Lebreux B., Aubert A. Treatment of canine parvoviral enteritis with interferon-omega in a placebo-controlled challenge trial. Vet. Microbiol. 89(2-3):2002;115-127
26. Meager, A., 1998. Interferons alpha, beta, and omega. In: Mire-Sluis, A., Thorpe, R. (Eds.), Cytokines. Academic Press, California, pp. 361-389.
27. Mochizuki M., Nakatani H., Yoshida M. Inhibitory effects of recombinant feline interferon on the replication of feline enteropathogenic viruses in vitro. Vet. Microbiol. 39(1-2):1994;145-152
28. Mouchel-Vielh E., Lutfalla G., Mogensen K.E., Uze G. Specific antiviral activities of the human alpha interferons are determined at the level of receptor (IFNAR) structure. FEBS Lett. 313:1992;255-259
29. Nakamura N., Sudo T., Matsuda S., Yanai A. Molecular cloning of feline interferon cDNA by direct expression. Biosci. Biotechnol. Biochem. 56(2):1992;211-214
30. Orr C.M., Gaskell C.J., Gaskell R.M. Interaction of a combined feline viral rhinotracheitis-feline calicivirus vaccine and the FVR carrier state. Vet. Rec. 103(10):1978;200-202
31. Ortaldo J.R., Herbermann R.B., Harvey C., Osheroff P., Pan Y.-C.E., Kelder B., Pestka S. A species of human α interferon that lacks the ability to boost human natural killer activity. Proc. Natl. Acad. Sci. U.S.A. 81:1984;4926-4929
32. Osorio J.E., Thomlinson C.C., Frank R.S., Haanes E.J., Rushlow K., Haynes J.R., Stinchcomb D.T. Immunization of dogs and cats with a DNA vaccine against rabies virus. Vaccine. 17:1999;1109-1116
33. Panaretakis T., Pokrovskaja K., Shoshan M.C., Grander D. Interferon-alpha-induced apoptosis in U266 cells is associated with activation of the proapoptotic Bcl-2 family members Bak and Bax. Oncogene. 22(29):2003;4543-4556
34. Patnaik A.K., Mooney S. Feline melanoma: a comparative study of ocular, oral, and dermal neoplasms. Vet. Pathol. 25(2):1988;105-112
35. Pavlovic J., Zurcher T., Haller O., Staeheli P. Resistance to influenza virus and vesicular stomatitis virus conferred by expression of human MxA protein. J. Virol. 64(7):1990;3370-3375
36. Priosoeryanto B.P., Tateyama S., Yamaguchi R., Uchida K. Antiproliferation and colony-forming inhibition activities of recombinant feline interferon (rfeIFN) on various cells in vitro. Can. J. Vet. Res. 59:1995;67-69
37. Samuel C.E. Antiviral actions of interferons. Clin. Microb. Rev. 14(4):2001;778-809
38. Sandrock M., Frese M., Haller O., Kochs G. Interferon-induced rat Mx proteins confer resistance to Rift Valley fever virus and other arthropod-borne viruses. J. Interferon Cytokine Res. 21:2001;663-668
39. Sangfelt O., Erickson S., Castro J., Heiden T., Einhorn S., Grander D. Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines. Cell Growth Differ. 8(3):1997;343-352
40. Sen G.C., Herz R., Davatelis V., Pestka S. Antiviral and protein-inducing activities of recombinant human leukocyte interferons and their hybrids. J. Virol. 50(2):1984;445-450
41. Sykes J.E. Feline upper respiratory tract pathogens: herpesvirus-1 and calicivirus. Comp. Cont. Educ. Pract. Vet. 23(2):2001;166-176
42. Tateyama S., Priosoeryanto B.P., Yamaguchi R., Uchida K. In vitro growth inhibition activities of recombinant feline interferon on all lines derived from canine tumours. Res. Vet. Sci. 59(3):1995;275-277
43. Thyrell L., Erickson S., Zhivotovsky B., Pokrovskaja K., Sangfelt O., Castro J., Einhorn S., Grander D. Mechanisms of interferon-alpha induced apoptosis in malignant cells. Oncogene. 21:2002;1251-1262
44. Tossing G. New developments in interferon therapy. Eur. J. Med. Res. 6:2001;47-65
45. Ueda Y., Sakurai T., Yanai A. Homogenous production of feline interferon in silkworm by replacing single amino acid code in signal peptide region in recombinant baculovirus and characterization of the product. J. Vet. Med. Sci. 55:1993;251-258
46. Vogel, S.N., Friedman, R.M., Hogan, M.M., 1991. Measurement of antiviral activity induced by interferons α, β and γ. In: Coligan, J.E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. (Eds.), Current Protocols in Immunology. Wiley, New York, pp. 6.9.1-6.9.4.
47. Wardley R.C., Povey R.C. The pathology and sites of persistence associated with three different strains of feline calicivirus. Res. Vet. Sci. 23(1):1977;15-19
48. Weber F., Haller O., Kochs G. MxA GTPase blocks reporter gene expression of reconstituted Thogoto virus ribonucleoprotein complexes. J. Virol. 74(1):2000;560-563
49. Weck P.K., Apperson S., Stebbing N., Gray P.W., Leung D., Shepard H.M., Goeddel D.V. Antiviral activities of hybrids of two major human leukocyte interferons. Nucl. Acids Res. 9(22):1981;6153-6156
50. Weiss R.C., Toivio-Kinnucan M. Inhibition of feline infectious peritonitis virus replication by recombinant human leukocyte (alpha) interferon and feline fibroblastic (beta) interferon. Am. J. Vet. Res. 49(8):1988;1329-1335
51. Weiss R.C. Synergistic antiviral activities of acyclovir and recombinant human leukocyte (alpha) interferon on feline herpesvirus replication. Am. J. Vet. Res. 50(10):1989;1672-1677
52. Weiss R.C., Oostrom-Ram T. Inhibitory effects of ribavirin alone or combined with human alpha interferon on feline infectious peritonitis virus replication in vitro. Vet. Microbiol. 20(3):1989;255-265
53. Wonderling R., Powell T., Baldwin S., Morales T., Snyder S., Keiser K., Hunter S., Best E., McDermott M.J., Milhausen M. Cloning, expression, purification and biological activity of five feline type I interferons. Vet. Immunol. Immunopathol. 89:2002;13-27
54. Yanai Y., Sanou O., Yamamoto K., Yamauchi H., Ikegami H., Kurimoto M. The anti-tumor activities of interferon (IFN)-alpha in chronic myelogenous leukaemia (CML)-derived cell lines depends on the IFN-alpha subtypes. Cancer Lett. 185(2):2002;173-179
55. Yeow W.-S., Lawson C.M., Beilharz M.W. Antiviral activities of individual murine IFN-α subtypes in vivo: intramuscular injection of IFN expression constructs reduces cytomegalovirus replication. J. Immunol. 160:1998;2932-2939
56. Zeidner N.S., Myles M.H., Mathiason-DuBard C.K., Dreitz M.J., Mullins J.I., Hoover E.A. Alpha Interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob. Agents Chemother. 34(9):1990;1749-1756
57. Zeidner N.S., Rose L.M., Mathiason-DuBard C.K., Myles M.H., Hill D.L., Mullins J.I., Hoover E.A. Zidovudine in combination with alpha interferon and interleukin-2 as prophylactic therapy for FeLV-induced immunodeficiency syndrome (FeLV-FAIDS). J. Acquir. Immm. Deficiency Syndrome. 3(8):1990;787-796